Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 587

1.

Cytokines in the Treatment of Cancer.

Conlon KC, Miljkovic MD, Waldmann TA.

J Interferon Cytokine Res. 2018 Jun 11. doi: 10.1089/jir.2018.0019. [Epub ahead of print]

PMID:
29889594
2.

Protection by universal influenza vaccine is mediated by memory CD4 T cells.

Valkenburg SA, Li OTW, Li A, Bull M, Waldmann TA, Perera LP, Peiris M, Poon LLM.

Vaccine. 2018 Jul 5;36(29):4198-4206. doi: 10.1016/j.vaccine.2018.06.007. Epub 2018 Jun 7.

PMID:
29887326
3.

Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.

Ratner L, Waldmann TA, Janakiram M, Brammer JE.

N Engl J Med. 2018 May 17;378(20):1947-1948. doi: 10.1056/NEJMc1803181. No abstract available.

4.

Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells.

Nagy É, Mocsár G, Sebestyén V, Volkó J, Papp F, Tóth K, Damjanovich S, Panyi G, Waldmann TA, Bodnár A, Vámosi G.

Biophys J. 2018 May 22;114(10):2473-2482. doi: 10.1016/j.bpj.2018.04.038. Epub 2018 May 10.

PMID:
29754714
5.

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.

Lu L, Zhu F, Zhang M, Li Y, Drennan AC, Kimpara S, Rumball I, Selzer C, Cameron H, Kellicut A, Kelm A, Wang F, Waldmann TA, Rui L.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E498-E505. doi: 10.1073/pnas.1715118115. Epub 2018 Jan 2.

6.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

PMID:
29203590
7.

Cytokines in Cancer Immunotherapy.

Waldmann TA.

Cold Spring Harb Perspect Biol. 2017 Nov 3. pii: a028472. doi: 10.1101/cshperspect.a028472. [Epub ahead of print]

PMID:
29101107
8.

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16. No abstract available.

PMID:
29032710
9.

IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities.

Dubois S, Conlon KC, Müller JR, Hsu-Albert J, Beltran N, Bryant BR, Waldmann TA.

Cancer Immunol Res. 2017 Oct;5(10):929-938. doi: 10.1158/2326-6066.CIR-17-0279. Epub 2017 Aug 25.

PMID:
28842470
10.

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY.

Am J Hematol. 2017 Sep;92(9):892-901. doi: 10.1002/ajh.24794. Epub 2017 Jun 5.

PMID:
28543380
11.

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.

12.

JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.

Waldmann TA.

Mol Cell Endocrinol. 2017 Aug 15;451:66-70. doi: 10.1016/j.mce.2017.02.019. Epub 2017 Feb 15. Review.

PMID:
28214593
13.

Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Waldmann TA, Chen J.

Annu Rev Immunol. 2017 Apr 26;35:533-550. doi: 10.1146/annurev-immunol-110416-120628. Epub 2017 Feb 9. Review.

PMID:
28182501
14.

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.

Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC.

Clin Cancer Res. 2017 Jan 1;23(1):35-42. doi: 10.1158/1078-0432.CCR-16-1022. Epub 2016 Aug 2.

15.

MHC I Expression Regulates Co-clustering and Mobility of Interleukin-2 and -15 Receptors in T Cells.

Mocsár G, Volkó J, Rönnlund D, Widengren J, Nagy P, Szöllősi J, Tóth K, Goldman CK, Damjanovich S, Waldmann TA, Bodnár A, Vámosi G.

Biophys J. 2016 Jul 12;111(1):100-12. doi: 10.1016/j.bpj.2016.05.044.

16.

Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.

Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, Yang Y, Webster DE, Rui L, Kohlhammer H, Nakagawa M, Waldmann TA, Staudt LM.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2039-46. doi: 10.1073/pnas.1600557113. Epub 2016 Mar 18.

17.

Erratum to: 'Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia'.

Yeh CH, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, Nicot C.

Mol Cancer. 2016 Mar 2;15:20. doi: 10.1186/s12943-016-0504-8. No abstract available.

18.

Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.

Yeh CH, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, Nicot C.

Mol Cancer. 2016 Feb 16;15:15. doi: 10.1186/s12943-016-0500-z. Erratum in: Mol Cancer. 2016;15:20. Toshiki, Watanabe [Corrected to Watanabe, Toshiki].

19.

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.

Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, Guha R, Ferrer M, Thomas CJ, Waldmann TA.

Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1624-9. doi: 10.1073/pnas.1524668113. Epub 2016 Jan 25.

20.

IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.

Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E.

Cancer Res. 2015 Dec 15;75(24):5187-5193. doi: 10.1158/0008-5472.CAN-15-1498. Epub 2015 Dec 1. Review.

21.

Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes.

Yu H, Sui Y, Wang Y, Sato N, Frey B, Xia Z, Waldmann TA, Berzofsky J.

PLoS One. 2015 Nov 23;10(11):e0143001. doi: 10.1371/journal.pone.0143001. eCollection 2015.

22.

Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein.

Parra M, Liu X, Derrick SC, Yang A, Molina-Cruz A, Barillas-Mury C, Zheng H, Thao Pham P, Sedegah M, Belmonte A, Litilit DD, Waldmann TA, Kumar S, Morris SL, Perera LP.

PLoS One. 2015 Oct 27;10(10):e0141141. doi: 10.1371/journal.pone.0141141. eCollection 2015.

23.

Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

Yokoyama S, Perera PY, Terawaki S, Watanabe N, Kaminuma O, Waldmann TA, Hiroi T, Perera LP.

J Clin Immunol. 2015 Oct;35(7):661-7. doi: 10.1007/s10875-015-0203-z. Epub 2015 Oct 9.

PMID:
26453583
24.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

25.

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.

Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, Wen B, Maeda M, Shinn P, Ferrer M, Conlon KD, Bamford RN, O'Shea JJ, Thomas CJ, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5. doi: 10.1073/pnas.1516208112. Epub 2015 Sep 22.

26.

IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma.

Jain S, Chen J, Nicolae A, Wang H, Shin DM, Adkins EB, Sproule TJ, Leeth CM, Sakai T, Kovalchuk AL, Raffeld M, Ward JM, Rehg JE, Waldmann TA, Jaffe ES, Roopenian DC, Morse HC 3rd.

Am J Pathol. 2015 Nov;185(11):3102-14. doi: 10.1016/j.ajpath.2015.07.021. Epub 2015 Sep 9.

27.

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.

Kreitman RJ, Stetler-Stevenson M, Jaffe ES, Conlon KC, Steinberg SM, Wilson W, Waldmann TA, Pastan I.

Clin Cancer Res. 2016 Jan 15;22(2):310-8. doi: 10.1158/1078-0432.CCR-15-1412. Epub 2015 Sep 8.

28.

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ.

Immunity. 2015 May 19;42(5):826-38. doi: 10.1016/j.immuni.2015.04.018.

29.

Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.

Zhang Y, Tian S, Liu Z, Zhang J, Zhang M, Bosenberg MW, Kedl RM, Waldmann TA, Storkus WJ, Falo LD Jr, You Z.

Oncoimmunology. 2014 Dec 15;3(10):e959321. eCollection 2014 Nov.

30.
31.

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, Telford WG, Palmer DC, Franco Z, Sukumar M, Roychoudhuri R, Clever D, Klebanoff CA, Surh CD, Waldmann TA, Restifo NP, Gattinoni L.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):476-81. doi: 10.1073/pnas.1422916112. Epub 2014 Dec 29.

32.

Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.

Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, Yu X, Waldmann TA, Staudt LM.

J Exp Med. 2014 Dec 15;211(13):2497-505. doi: 10.1084/jem.20140987. Epub 2014 Dec 8.

33.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.

34.

Interleukin-15 in the treatment of cancer.

Waldmann TA.

Expert Rev Clin Immunol. 2014 Dec;10(12):1689-701. doi: 10.1586/1744666X.2014.973856. Epub 2014 Oct 31. Review.

PMID:
25359408
35.

Distinct spatial relationship of the interleukin-9 receptor with interleukin-2 receptor and major histocompatibility complex glycoproteins in human T lymphoma cells.

Nizsalóczki E, Csomós I, Nagy P, Fazekas Z, Goldman CK, Waldmann TA, Damjanovich S, Vámosi G, Mátyus L, Bodnár A.

Chemphyschem. 2014 Dec 15;15(18):3969-78. doi: 10.1002/cphc.201402501. Epub 2014 Oct 8.

36.

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, Fleisher TA, Turner M, Urquhart NE, Wharfe GH, Figg WD, Peer CJ, Goldman CK, Waldmann TA, Morris JC.

Clin Immunol. 2014 Dec;155(2):176-87. doi: 10.1016/j.clim.2014.09.012. Epub 2014 Sep 28.

37.

IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.

Yu P, Bamford RN, Waldmann TA.

Eur J Immunol. 2014 Nov;44(11):3330-41. doi: 10.1002/eji.201444675.

38.

Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.

Yu P, Petrus MN, Ju W, Zhang M, Conlon KC, Nakagawa M, Maeda M, Bamford RN, Waldmann TA.

Leukemia. 2015 Mar;29(3):556-66. doi: 10.1038/leu.2014.241. Epub 2014 Aug 14.

39.

Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells.

Müller JR, Waldmann TA, Dubois S.

PLoS One. 2014 Aug 7;9(8):e102793. doi: 10.1371/journal.pone.0102793. eCollection 2014.

40.

Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas.

Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, Chen J, Waldmann TA, Jaffe ES, Raffeld M.

Leukemia. 2014 Nov;28(11):2244-8. doi: 10.1038/leu.2014.200. Epub 2014 Jun 20. No abstract available.

PMID:
24947020
41.

Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia.

Ju W, Zhang M, Petrus M, Maeda M, Pise-Masison CA, Waldmann TA.

Retrovirology. 2014 Jun 2;11:43. doi: 10.1186/1742-4690-11-43.

42.

IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.

Valkenburg SA, Li OT, Mak PW, Mok CK, Nicholls JM, Guan Y, Waldmann TA, Peiris JS, Perera LP, Poon LL.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5676-81. doi: 10.1073/pnas.1403684111. Epub 2014 Mar 31.

43.
44.

Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.

Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, Waldmann TA, Steel JC.

Gene Ther. 2014 Apr;21(4):393-401. doi: 10.1038/gt.2014.10. Epub 2014 Feb 27.

45.

The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.

Waldmann TA.

J Investig Dermatol Symp Proc. 2013 Dec;16(1):S28-30. doi: 10.1038/jidsymp.2013.8. Review.

46.

Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα.

Chen J, Feigenbaum L, Awasthi P, Butcher DO, Anver MR, Golubeva YG, Bamford R, Zhang X, St Claire MB, Thomas CJ, Discepolo V, Jabri B, Waldmann TA.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13534-9. doi: 10.1073/pnas.1312911110. Epub 2013 Jul 31.

47.

Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.

Merkel TJ, Perera PY, Lee GM, Verma A, Hiroi T, Yokote H, Waldmann TA, Perera LP.

Hum Vaccin Immunother. 2013 Sep;9(9):1841-8. doi: 10.4161/hv.25337. Epub 2013 Jun 20.

48.

Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation.

Bellon M, Ko NL, Lee MJ, Yao Y, Waldmann TA, Trepel JB, Nicot C.

Blood. 2013 Jun 20;121(25):5045-54. doi: 10.1182/blood-2012-07-439109. Epub 2013 May 9.

49.

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.

Blood. 2013 Mar 14;121(11):2029-37. doi: 10.1182/blood-2012-05-427773. Epub 2013 Jan 15.

50.

GVL for ATL?

Shah NN, Waldmann TA.

Blood. 2013 Jan 3;121(1):6-7. doi: 10.1182/blood-2012-11-464628. No abstract available.

Supplemental Content

Loading ...
Support Center